Reply to the Comment on "Design, synthesis, anticancer activity and molecular docking of quinoline-based dihydrazone derivatives" by R. Weiskirchen, RSC Adv., 2025, 15, https://doi.org/10.1039/D5RA00388A
- PMID: 41280225
- PMCID: PMC12631750
- DOI: 10.1039/d5ra02571k
Reply to the Comment on "Design, synthesis, anticancer activity and molecular docking of quinoline-based dihydrazone derivatives" by R. Weiskirchen, RSC Adv., 2025, 15, https://doi.org/10.1039/D5RA00388A
Abstract
In this reply, Lu et al. address the cell line contamination concerns raised in the comment on their original paper (RSC Adv., 2025, 15, 231-243). To ensure the reliability of their conclusions, the key experiments were repeated using authenticated cell lines (Huh-7 and HUVEC), confirming the reproducibility and validity of the reported results.
This journal is © The Royal Society of Chemistry.
Conflict of interest statement
All authors declare that they have no relevant conflict of interest.
Comment on
-
Comment on "Design, synthesis, anticancer activity and molecular docking of quinoline-based dihydrazone derivatives" by J.-X. Lu, H.-R. Lan, D. Zeng, J.-Y. Song, Y.-T. Hao, A.-P. Xing, A. Shen, and J. Yuan, RSC Adv., 2025, 15, 231-243.RSC Adv. 2025 Nov 14;15(52):44437-44438. doi: 10.1039/d5ra00388a. eCollection 2025 Nov 11. RSC Adv. 2025. PMID: 41244744 Free PMC article.
References
-
- Masters J. R. Nat. Rev. Cancer. 2002;2:315–319. - PubMed
-
- Cellosaurus, MCF-7 (CVCL_0031), https://www.cellosaurus.org/CVCL_0031, accessed July 2025
-
- ATCC, MCF-7 (ATCC®HTB-22™), https://www.atcc.org/products/htb-22, accessed July 2025
-
- Pan C. Xu L. Tang Y. Liu A. A. Zhang L. Nat. Protoc. 2020;15:406–428.
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous
